Medication Adherence Clinical Trial
Official title:
Effects of Adherence Therapy on Medication Adherence in Patients With Schizophrenia Spectrum Disorder: A Randomized Controlled Trial
Verified date | October 2023 |
Source | National Yang Ming University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study will explore the effect of Adherence Therapy(AT) on medication adherence in patients with schizophrenia spectrum disorder.
Status | Completed |
Enrollment | 120 |
Est. completion date | September 30, 2019 |
Est. primary completion date | August 30, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 20 Years to 64 Years |
Eligibility | Inclusion Criteria: - aged 20-64 - were Chinese speaking or Taiwanese speaking; - diagnosed with schizophrenia or schizoaffective disorder - recent history of non-adherence to antipsychotic medication. 1. Non-adherence to medication was defined as a recent history of cessation of psychiatric admission for more than one month at a time 2. The patient recently (half year) relapse of mental illness 3. Family and Health care worker state that the patient has taken irregular medication - demonstrated cognitive understanding of the research plan and provided consent. Exclusion Criteria: - discharged from hospital for at least 3 months - no intellectual disability, organic brain diseases or Cognitive impairment - no alcohol or sub-stance abuse problems - were not attending medication management program . |
Country | Name | City | State |
---|---|---|---|
Taiwan | National Yang-Ming University | Taipei City |
Lead Sponsor | Collaborator |
---|---|
National Yang Ming University | Taipei Veterans General Hospital, Taiwan |
Taiwan,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Medication Adherence Rating Scale | The Medication Adherence Rating Scale was developed by Thompson et al. (2000). It evaluates the adherence behavior and attitude of the patient within the previous week. There are 10 close-ended questions (yes/no answers) in the questionnaire. | for two study groups at baseline(T0) and after 4 session interim analysis (T1;9-12 weeks) and 8 session after intervention (T2;21-28 weeks). | |
Secondary | Schedule for the Assessment of Insight, SAI | The Schedule of Assessment of Insight (SAI) measures multiple dimensions of insight, including compliance with treatment, recognition of illness, re-labeling of psychotic phenomena, and awareness of changes in mental functioning and psychosocial consequences of the illness.The maximum score of the SAI is 14, with higher SAI scores indicating greater insight. The Cronbach alpha for the SAI was 0.96, and inter-rater reliability (r) between the two research psychiatrists was .92 in the present study. | for two study groups at baseline(T0) and after 4 session interim analysis(T1;9-12 weeks) and 8 session after intervention(T2;21-28 weeks). | |
Secondary | Positive and Negative Syndrome Scale, PANSS | PANSS assessed the severity of psychotic symptoms in terms of three subscales, including positive symptoms (hallucinations,delusional beliefs, and 30-item 7point Likert scale (from 1-'Absent' to 7-'Extremely'). | for two study groups at baseline(T0) and after 4 session interim analysis(T1;9-12 weeks) and 8 session after intervention(T2;21-28 weeks). | |
Secondary | Self-Appraisal of Illness Questionnaire, SAIQ | The Self-Appraisal of Illness Questionnaire (SAIQ) was used to assess patients' insight into their illness.The need for treatment and presence/outcome of illness subscales of SAIQ have been used as brief screening instruments for schizophrenic patients who may be at risk for treatment noncompliance. Lower SAIQ subscale scores indicate reduced awareness of the psychiatric illness. This scale is a self reporting instrument composed of 17 items in which participants are asked to rate the extent to which they agreed with each statement by using a 4-point Likert scale ranging from 0 (ie, "do not agree at all") to 3 (ie, "agree completely").
The internal consistency of the scale was 0.867, and the retest reliability was 0.82. |
for two study groups at baseline(T0) and after 4 session interim analysis(T1;9-12 weeks) and 8 session after intervention(T2;21-28 weeks). |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04709640 -
Pilot Study to Improve Medication Management in Older Adults
|
N/A | |
Completed |
NCT03257579 -
Myocardial Infarction Prescription Duration Adherence Study
|
N/A | |
Completed |
NCT05376397 -
Testing THRIVE 365 for Black Sexual Minority Men (On The Daily)
|
N/A | |
Withdrawn |
NCT03427008 -
A Pilot Study of mDOT for Immunosuppressant Adherence in Adult Kidney Transplant Recipients
|
N/A | |
Completed |
NCT03805451 -
Life Steps for PrEP for Youth
|
N/A | |
Withdrawn |
NCT03292393 -
Social Norms and Antihypertensive Medication Adherence
|
N/A | |
Not yet recruiting |
NCT02876848 -
A Novel E-Health Approach in Optimizing Treatment for Seniors (OPTIMUM Study)
|
N/A | |
Completed |
NCT02823795 -
The Supporting Patient Activation in Transition to Home Intervention
|
N/A | |
Completed |
NCT02914730 -
Insulin Dosing Practices in Persons With Diabetes on Multiple Daily Injections
|
||
Completed |
NCT02066935 -
Non-adherence to Immunosuppressives in Kidney Transplantation in Brazil Multicenter Study
|
||
Completed |
NCT02797262 -
Measuring and Monitoring Adherence to ART With Pill Ingestible Sensor System
|
N/A | |
Completed |
NCT01934608 -
The Effect of Synching Prescription Refills on Adherence
|
N/A | |
Completed |
NCT01741311 -
Secondary HIV Prevention and Adherence Among HIV-infected Drug Users
|
N/A | |
Completed |
NCT01770314 -
Study to Test the Efficacy of Online Education to Increase Safe Use of Opioid Medication.
|
Phase 2 | |
Recruiting |
NCT01105104 -
An Enhanced Medication Monitoring Program
|
Phase 1 | |
Completed |
NCT01859273 -
Adherence Enhancement for Renal Transplant Patients
|
N/A | |
Withdrawn |
NCT01430702 -
Feasibility of Using a Telemedicine Medication Delivery Unit for Older Adults
|
N/A | |
Completed |
NCT01118208 -
Blister Packaging Medication to Increase Treatment Adherence and Clinical Response
|
N/A | |
Completed |
NCT00848224 -
Improving Adherence to Pharmacological Treatment
|
N/A | |
Completed |
NCT06034301 -
Pill Bottle vs Reminder App
|
N/A |